Compare Quest Diagnostics Inc (DGX) vs Devon Energy Corp (DVN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Devon Energy Corp — how do they compare? Quest Diagnostics Inc trades at $204.68 (market cap $22.80B), while Devon Energy Corp trades at $42.63 (market cap $50.44B). The key difference: Devon Energy Corp is far larger — about 2.2× Quest Diagnostics Inc's market cap, and Devon Energy Corp pays the higher dividend (2.38%). Which is the better fit depends on your goals.
| DGX | DVN | |
|---|---|---|
Market Cap | $22.80B | $50.44B |
Sector | Health | Energy |
52-Week High | $216.02 | $52.07 |
52-Week Low | $166.42 | $31.74 |
Enterprise Value | $28.82B | $57.22B |
Dividend Yield | 1.67% | 2.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Devon Energy (DVN) trades at $43.73, up 3.55% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings show mixed results, beating in Q3 and Q4 2025 but missing in Q1 2026, with Q2 results pending. The company maintains solid profitability with a 13.71% net margin and robust cash flow, supported by the Coterra acquisition targeting $2 billion in synergies by 2027. Debt-to-asset ratio improved to 26.54% in 2025, reflecting disciplined financial management.
Outlook remains positive with a consensus price target of $60.55, implying significant upside. Key opportunities include synergy realization and free cash flow growth, while risks involve oil price volatility and activist investor pressure for asset sales. The stock offers value with a P/E of 12.18, below sector averages, but investors should monitor Q2 earnings due August 4 for confirmation of growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Devon Energy Corp
Devon Energy, based in Oklahoma City, is one of the largest independent exploration and production companies in North America. The firm's asset base is spread throughout onshore North America and includes exposure to the Delaware, STACK, Eagle Ford, Powder River Basin, and Bakken plays. At year-end 2021, Devon's proved reserves totaled 1.6 billion barrels of oil equivalent, and net production that year was 572 thousand boe/d, of which oil and natural gas liquids made up 74% of production, with natural gas accounting for the remainder.
Read more on DVN →
